CSS
BOLD

Cubist Systematic Strategies’s Audentes Therapeutics, Inc BOLD Stock Holding History

Cubist Systematic Strategies’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-28,916
Closed -$812K – 2650
2019
Q3 		$812K Buy
28,916
+9,459
+49% +$323K 0.02% 1083
2019
Q2 		$737K Buy
19,457
+18,676
+2,391% +$718K 0.01% 1216
2019
Q1 		$30K Sell
781
-27,626
-97% -$792K ﹤0.01% 2155
2018
Q4 		$606K Buy
+28,407
New +$733K 0.03% 837
2018
Q3 		– Sell
-5,948
Closed -$227K – 2190
2018
Q2 		$227K Sell
5,948
-835
-12% -$30.9K 0.01% 1270
2018
Q1 		$204K Buy
+6,783
New +$230K 0.01% 1392
2017
Q3 		– Sell
-1,192
Closed -$23K – 2091
2017
Q2 		$23K Buy
+1,192
New +$19K ﹤0.01% 1598

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Cubist Systematic Strategies's BOLD Position: Q4 2019 in Review

Cubist Systematic Strategies sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 28,916 shares — an estimated $812K sold.

Cubist Systematic Strategies first reported a position in BOLD in Q2 2017 and held it in 7 quarters. The position peaked at $812K in Q3 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Cubist Systematic Strategies reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Cubist Systematic Strategies sold 28,916 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $812K.
  • Cubist Systematic Strategies first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 7 quarters.
  • Cubist Systematic Strategies's Audentes Therapeutics, Inc position peaked at $812K in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Cubist Systematic Strategies's 13F filing for Q4 2019, filed 14 Feb 2020.